Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK R&D Initiative Sees Early Success: Phase II NCEs Up Three-Fold

Executive Summary

GlaxoSmithKline's R&D productivity program has experienced some early successes in the number of compounds coming out of the early-stage pipeline
Advertisement

Related Content

GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis
GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
GSK Trades In Anti-Infective R&D Model, Starts CEDD For Infectious Disease
GSK Recipe For R&D: Keep Drugs In Phase II Longer, Foster Accountability
Pharma Firms Debate Novel Biotech Deals: How Much Competition Is Healthy?
GSK Switch Success: Paxil CR Has 31% Of New Scripts; Augmentin ES, 49%
FDA Faster Approval Times For 2002 NMEs Aided By Resubmissions
FDA Faster Approval Times For 2002 NMEs Aided By Resubmissions
GSK Florida Medicaid Deal Close; Discounts Are Not "Difficult," Garnier Says
Advertisement
UsernamePublicRestriction

Register

PS041276

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel